Talheira Appoints Dr. David J. Bearss to Board

TL;DR

Talheira adds biotech vet Dr. Bearss to the board. Big moves ahead?

AI Summary

Talheira, Inc. announced on June 24, 2024, the election of Dr. David J. Bearss to its Board of Directors. Dr. Bearss brings extensive experience in drug development and commercialization, having previously held leadership roles at notable biotechnology companies. His appointment is expected to strengthen the company's strategic direction and operational capabilities.

Why It Matters

The addition of an experienced director like Dr. Bearss can signal confidence in the company's future prospects and potentially enhance its ability to navigate complex drug development challenges.

Risk Assessment

Risk Level: low — This filing primarily concerns a board appointment, which is a routine corporate governance event with limited immediate financial risk.

Key Players & Entities

• Talheira, Inc. (company) — Registrant
• Dr. David J. Bearss (person) — Newly elected Director
• ACELRX PHARMACEUTICALS INC (company) — Former Company Name

FAQ

Key Financial Figures

• $0.001 — ge on which registered Common Stock , $0.001 par value TLPH The Nasdaq Global Mar

Filing Documents

• acrx20240624_8k.htm (8-K) — 54KB
• ex_691933.htm (EX-10.1) — 218KB
• ex_691934.htm (EX-10.2) — 80KB
• 0001437749-24-021108.txt ( ) — 544KB
• tlph-20240624.xsd (EX-101.SCH) — 3KB
• tlph-20240624_def.xml (EX-101.DEF) — 11KB
• tlph-20240624_lab.xml (EX-101.LAB) — 15KB
• tlph-20240624_pre.xml (EX-101.PRE) — 11KB
• acrx20240624_8k_htm.xml (XML) — 3KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. The Annual Meeting of the Company was held on June 24, 2024. Proxies for the Annual Meeting were solicited by the Board pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended, and there was no solicitation in opposition. At the Annual Meeting, a total of 9,562,803 shares were represented in person or by proxy out of the 16,992,977 shares of common stock entitled to vote as of April 26, 2024, the record date for the Annual Meeting. The final votes on the proposals presented at the Annual Meeting were as follows: Proposal No. 1 Adrian Adams and Jill Broadfoot were elected as Class I directors, by a plurality of the votes entitled to vote on the election of directors, to hold office until the 2027 Annual Meeting of Stockholders by the following vote: Nominee For Withheld Broker Non-Votes Adrian Adams 5,249,851 320,764 3,992,188 Jill Broadfoot 5,253,667 316,948 3,992,188 In addition to the directors elected above, Vincent J. Angotti, Abhinav Jain, and Stephen J. Hoffman, M.D., Ph.D. will continue to serve as directors until the 2025 Annual Meeting of Stockholders, and Marina Bozilenko and Mark Wan will continue to serve as directors until the 2026 Annual Meeting of Stockholders, in each case until their successors are elected and qualified, or until their earlier death, resignation or removal. Proposal No. 2 The selection by the Audit Committee of the Board of BPM LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024 was ratified by the following vote: For Against Abstain Broker Non-Votes 9,149,535 329,576 83,692 — Proposal No. 3 The compensation paid to the Company's named executive officers, as disclosed pursuant to Item 402 of Regulation S-K, compensation tables and narrative discussion was approved, on an advisory basis, by the following vote: For Against Abstain Broker Non-Vo

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1+ Amended and Restated 2020 Equity Incentive Plan 10.2+ Amended and Restated 2011 Employee Stock Purchase Plan 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) + Indicates management contract or compensatory plan

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 24, 2024 TALPHERA, INC. By: /s/ Raffi Asadorian Raffi Asadorian Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR